Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?
Öz
Objective: Many new inflammatory and metabolic markers are considered to be involved in etiology of Polycystic ovary syndrome (PCOS). R-spondin-1 (Rspo1) is a member of the roof plate-specific spondin protein family. Rspo1 levels have been associated with obesity and insulin resistance. We aimed to investigate whether Rspo1 has a role in the pathophysiology of PCOS.
Materials and Methods: This cross-sectional study was planned with newly diagnosed and untreated PCOS cases and a control group without PCOS. Patients with PCOS and healty participants were compared for Rspo1 levels. In addition, the PCOS group was also grouped according to body mass index (BMI) and Ferriman Gallwey scores (FGS) and compared in terms of Rsop1 levels.
Results: A total of 47 patients in the PCOS group and 36 participants in the control group, as total 83 participants were included in the study. PCOS and control groups had similar age and BMI. As compared to the control group, PCOS patients had significantly higher FGS, homeostasis model assessment of insulin resistance scores, Rspo1, and total testosterone levels (p<0.001, p=0.01, p=0.02, p=0.001 respectively). When subclassing PCOS patients according to BMI and FGS values, there was no statistically significant difference between Rspo1 levels in terms of both BMI and FGS values. Moreover, Rspo1 showed a significant positive correlation with total testosterone and dehydroepiandrosterone sulfate levels (p=0.03, r=0.23; p=0.08, r=0.30, respectively).
Conclusion: Rspo-1 may be associated with PCOS pathophysiology via total testosterone and dehydroepiandrosterone sulphate. Further molecular and genetic studies are needed to support this hypothesis.
Anahtar Kelimeler
R-spondin-1, Polycystic ovary syndrome, Ferriman Gallwey scores
Destekleyen Kurum
none
Proje Numarası
none
Teşekkür
none
Kaynakça
- Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38. e25.
- Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(1):1-17.
- Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-31.
- Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26(2):251-82.
- Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6):2453-5.
- Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res. 2003;11(8):987-96.
- Frishman WH. Biologic markers as predictors of cardiovascular disease. Am J Med. 1998;104(6A):18S-27S.
- Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24(3):278-301.
- Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448-54.
- Usta A, Avci E, Bulbul CB, Kadi H, Adali E. The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome. Reprod Biol Endocrinol. 2018;16(1):34.